Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

被引:57
作者
Jiang, Chunyang [1 ]
Meng, Lingxiang [2 ]
Yang, Bingjun [1 ]
Luo, Xin [3 ]
机构
[1] Tianjin Union Med Ctr, Dept Thorac Surg, 190 Jieyuan Rd, Tianjin 300121, Peoples R China
[2] Tianjin Union Med Ctr, Anorectal Surg Ctr, Dept Anorectal Surg, Tianjin, Peoples R China
[3] Second Affiliated Hosp, Gansu Med Coll, Hosp PingLiang City 2, Dept Radiotherapy, Pingliang, Peoples R China
关键词
Cancer; CRISPR; Cas9; gene editing; therapy; ONE-STEP GENERATION; CELL LUNG-CANCER; COLORECTAL-CANCER; DNA METHYLATION; IN-VITRO; ACQUIRED-RESISTANCE; CHECKPOINT BLOCKADE; DRUG-RESISTANCE; PROTEIN-KINASE; BREAST-CANCER;
D O I
10.1111/cge.13589
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In recent years, gene editing, especially that using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9, has made great progress in the field of gene function. Rapid development of gene editing techniques has contributed to their significance in the field of medicine. Because the CRISPR/Cas9 gene editing tool is not only powerful but also has features such as strong specificity and high efficiency, it can accurately and rapidly screen the whole genome, facilitating the administration of gene therapy for specific diseases. In the field of tumor research, CRISPR/Cas9 can be used to edit genomes to explore the mechanisms of tumor occurrence, development, and metastasis. In these years, this system has been increasingly applied in tumor treatment research. CRISPR/Cas9 can be used to treat tumors by repairing mutations or knocking out specific genes. To date, numerous preliminary studies have been conducted on tumor treatment in related fields. CRISPR/Cas9 holds great promise for gene-level tumor treatment. Personalized and targeted therapy based on CRISPR/Cas9 will possibly shape the development of tumor therapy in the future. In this study, we review the findings of CRISPR/Cas9 for tumor treatment research to provide references for related future studies on the pathogenesis and clinical treatment of tumors.
引用
收藏
页码:73 / 88
页数:16
相关论文
共 166 条
[31]   ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy [J].
Elizalde, Patricia V. ;
Cordo Russo, Rosalia I. ;
Chervo, Maria F. ;
Schillaci, Roxana .
ENDOCRINE-RELATED CANCER, 2016, 23 (12) :T243-T257
[32]   CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma [J].
Engelholm, Lars H. ;
Riaz, Anjum ;
Serra, Denise ;
Dagnaes-Hansen, Frederik ;
Johansen, Jens V. ;
Santoni-Rugiu, Eric ;
Hansen, Steen H. ;
Niola, Francesco ;
Froedin, Morten .
GASTROENTEROLOGY, 2017, 153 (06) :1662-+
[33]   SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line [J].
Feng, Wen ;
Li, Hong-chang ;
Xu, Ke ;
Chen, Ya-feng ;
Pan, Li-yun ;
Mei, Yi ;
Cai, Han ;
Jiang, Yi-ming ;
Chen, Teng ;
Feng, Dian-xu .
GENE, 2016, 587 (01) :91-97
[34]   Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes [J].
Ferdosi, Shayesteh R. ;
Ewaisha, Radwa ;
Moghadam, Farzaneh ;
Krishnah, Sri ;
Park, Jin G. ;
Ebrahimkhani, Mo R. ;
Kiani, Samira ;
Anderson, Karen S. .
NATURE COMMUNICATIONS, 2019, 10 (1)
[35]   Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer [J].
Fletcher, Nicole M. ;
Belotte, Jimmy ;
Saed, Mohammed G. ;
Memaj, Ira ;
Diamond, Michael P. ;
Morris, Robert T. ;
Saed, Ghassan M. .
FREE RADICAL BIOLOGY AND MEDICINE, 2017, 102 :122-132
[36]   Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency [J].
Garcia-Tunon, Ignacio ;
Alonso-Perez, Veronica ;
Vuelta, Elena ;
Perez-Ramos, Sandra ;
Herrero, Maria ;
Mendez, Lucia ;
Maria Hernandez-Sanchez, Jesus ;
Martin-Izquierdo, Marta ;
Saldana, Raquel ;
Sevilla, Julian ;
Sanchez-Guijo, Fermin ;
Maria Hernandez-Rivas, Jesus ;
Sanchez-Martin, Manuel .
PLOS ONE, 2019, 14 (05)
[37]   The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia [J].
Garcia-Tunon, Ignacio ;
Hernandez-Sanchez, Maria ;
Luis Ordonez, Jose ;
Alonso-Perez, Veronica ;
Alamo-Quijada, Miguel ;
Benito, Rocio ;
Guerrero, Carmen ;
Maria Hernandez-Rivas, Jesus ;
Sanchez-Martin, Manuel .
ONCOTARGET, 2017, 8 (16) :26027-26040
[38]   Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy [J].
Gori, Jennifer L. ;
Hsu, Patrick D. ;
Maeder, Morgan L. ;
Shen, Shen ;
Welstead, G. Grant ;
Bumcrot, David .
HUMAN GENE THERAPY, 2015, 26 (07) :443-451
[39]   Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis [J].
Goswami, Sudeshna ;
Sharma-Walia, Neelam .
ONCOTARGET, 2016, 7 (37) :58953-58974
[40]   CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response [J].
Haapaniemi, Emma ;
Botla, Sandeep ;
Persson, Jenna ;
Schmierer, Bernhard ;
Taipale, Jussi .
NATURE MEDICINE, 2018, 24 (07) :927-+